Inactive Instrument

Nanoform Finland Oyj Stock Nasdaq Helsinki

Equities

FI4000330972

Biotechnology & Medical Research

Sales 2024 * 7.48M 7.97M Sales 2025 * 14.6M 15.55M Capitalization 199M 212M
Net income 2024 * -15M -15.98M Net income 2025 * -11M -11.72M EV / Sales 2024 * 22.5 x
Net cash position 2024 * 31M 33.03M Net cash position 2025 * 21.34M 22.73M EV / Sales 2025 * 12.2 x
P/E ratio 2024 *
-13 x
P/E ratio 2025 *
-18.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.1%
More Fundamentals * Assessed data
Dynamic Chart
Nanoform Finland to Deliver Nanomedicine Technology to Japan MT
Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan CI
Nanoform Teams Up with PlusVitech to Repurpose Anti-Nausea Drug for Lung Cancer Treatment MT
Nanoform Finland plc and Plusvitech Partner to Repurpose Aprepitant as A Treatment for Lung Cancer CI
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Nanoform Finland Oyj, 2023 Earnings Call, Feb 29, 2024
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation CI
Transcript : Nanoform Finland Oyj - Special Call
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide CI
Nanoform Finland Starts Clinical Trial for Nanocrystalline Alternative of Prostrate Cancer Drug MT
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide CI
Transcript : Nanoform Finland Oyj, Q3 2023 Earnings Call, Nov 22, 2023
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca MT
More news
Managers TitleAgeSince
Chief Executive Officer 55 14-12-31
Director of Finance/CFO 53 14-12-31
Investor Relations Contact - 19-04-30
Members of the board TitleAgeSince
Chairman 68 19-04-01
Director/Board Member 67 18-12-31
Director of Finance/CFO 53 14-12-31
More insiders
Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj’s business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group’s strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.
Calendar
More about the company